We are live on ! Find out more
MITO

Stealth BioTherapeutics Corp. ADS
MITO

Delisted

MITO was delisted on the 15th of November, 2022.

Back to rankings

12 hedge funds and large institutions have $277K invested in Stealth BioTherapeutics Corp. ADS in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% less capital invested

Capital invested by funds: $334K → $277K (-$57K)

37% less funds holding

Funds holding: 19 → 12 (-7)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 6

Holders
12
Holders Change
-7
Holders Change %
-36.84%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
5
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$23.4K
2
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$1.54K
3
Osaic Holdings
Osaic Holdings
Arizona
+$133

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$36K
2
VF
Virtu Financial
New York
-$25K
3
IC
Ikarian Capital
Texas
-$18.9K
4
HighTower Advisors
HighTower Advisors
Illinois
-$14K
5
Millennium Management
Millennium Management
New York
-$10K

MITO Hedge Fund Activity: Q3 2022 in Review

12 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Stealth BioTherapeutics Corp. ADS (MITO) for Q3 2022, worth a combined $277K — down 17% from $334K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of MITO and 0 opened new positions — a net loss of 6 holders — while 5 trimmed existing stakes and 3 added.

The largest buyer was Renaissance Technologies, adding an estimated $23.4K. The largest seller was Citadel Advisors, exiting entirely with an estimated $36K sold.

  • 12 institutional investors held Stealth BioTherapeutics Corp. ADS (MITO) as of Q3 2022, down from 19 in Q2 2022.
  • Funds reported $277K of Stealth BioTherapeutics Corp. ADS stock for Q3 2022, down 17% quarter-over-quarter.
  • 0 funds opened new Stealth BioTherapeutics Corp. ADS positions in Q3 2022 and 6 closed out, a net change of -6 holders.
  • The largest Stealth BioTherapeutics Corp. ADS buyer in Q3 2022 was Renaissance Technologies, an estimated $23.4K added.
  • The largest Stealth BioTherapeutics Corp. ADS seller in Q3 2022 was Citadel Advisors, an estimated $36K sold.

Based on aggregated 13F filings for Q3 2022.